NASDAQ:CBST - Cubist Pharmaceuticals Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Cubist Pharmaceuticals (NASDAQ:CBST)

Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST News and Ratings via Email

Sign-up to receive the latest news and ratings for CBST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Cubist Pharmaceuticals (NASDAQ:CBST) Frequently Asked Questions

What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) announced its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company earned $309.20 million during the quarter, compared to analyst estimates of $305.50 million. The company's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.

Who are some of Cubist Pharmaceuticals' key competitors?

Has Cubist Pharmaceuticals been receiving favorable news coverage?

Press coverage about CBST stock has been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cubist Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Cubist Pharmaceuticals?

Shares of CBST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Cubist Pharmaceuticals?

Cubist Pharmaceuticals' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.

MarketBeat Community Rating for Cubist Pharmaceuticals (CBST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe CBST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBST will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cubist Pharmaceuticals (NASDAQ:CBST) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/21/2016 forward)


Cubist Pharmaceuticals (NASDAQ:CBST) Earnings History and Estimates Chart

Earnings by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)

Cubist Pharmaceuticals (NASDAQ CBST) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/21/2014Q314$0.04$0.58$305.50 million$309.20 millionViewListenView Earnings Details
7/22/2014Q214$0.37$0.23$299.60 million$294.40 millionViewN/AView Earnings Details
4/22/2014Q114$0.34$0.10$285.24 million$261.20 millionViewN/AView Earnings Details
1/23/2014Q413$0.33$0.29$285.47 million$299.70 millionViewN/AView Earnings Details
10/22/2013Q3 2013$0.55$0.41$269.72 million$265.99 millionViewN/AView Earnings Details
7/18/2013Q2 2013$0.55$0.42$254.93 million$258.80 millionViewN/AView Earnings Details
4/18/2013Q1 2013$0.50$0.34$243.55 million$229.90 millionViewN/AView Earnings Details
1/23/2013Q4 2012$0.48$0.51$246.42 million$245.90 millionViewN/AView Earnings Details
10/18/2012$0.47$0.55ViewN/AView Earnings Details
7/19/2012$0.45$0.68ViewN/AView Earnings Details
4/18/2012$0.63$0.82ViewN/AView Earnings Details
1/19/2012$0.31$0.11ViewN/AView Earnings Details
10/19/2011$0.26$0.33ViewN/AView Earnings Details
7/14/2011$0.43($0.34)ViewN/AView Earnings Details
4/14/2011$0.26$0.34ViewN/AView Earnings Details
1/20/2011$0.34$0.24ViewN/AView Earnings Details
10/14/2010Q3 2010$0.41$0.50ViewN/AView Earnings Details
7/15/2010Q2 2010$0.41$0.45ViewN/AView Earnings Details
4/15/2010Q1 2010$0.35$0.34ViewN/AView Earnings Details
1/21/2010Q4 2009$0.41$0.45ViewN/AView Earnings Details
10/15/2009Q3 2009$0.33$0.42ViewN/AView Earnings Details
7/16/2009Q2 2009$0.28$0.40ViewN/AView Earnings Details
4/21/2009Q1 2009$0.14$0.13ViewN/AView Earnings Details
1/22/2009Q4 2008$0.52$0.67ViewN/AView Earnings Details
10/16/2008Q3 2008$0.34$0.44ViewN/AView Earnings Details
7/17/2008Q2 2008$0.10$0.34ViewN/AView Earnings Details
4/17/2008Q1 2008$0.27$0.29ViewN/AView Earnings Details
1/23/2008Q4 2007$0.17$0.16ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Cubist Pharmaceuticals (NASDAQ:CBST) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cubist Pharmaceuticals (NASDAQ CBST) Insider Trading and Institutional Ownership History

Insider Trading History for Cubist Pharmaceuticals (NASDAQ:CBST)

Cubist Pharmaceuticals (NASDAQ CBST) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2014Steven C GilmanEVPSell48,125$65.39$3,146,893.75View SEC Filing  
8/19/2014Gregory SteaSVPSell38,326$65.88$2,524,916.88View SEC Filing  
8/18/2014Nancy J HutsonDirectorSell9,000$65.00$585,000.00View SEC Filing  
8/18/2014Robert J PerezCOOSell1,003$63.68$63,871.04View SEC Filing  
7/28/2014Steven C GilmanEVPSell40,625$61.57$2,501,281.25View SEC Filing  
5/15/2014Michael BonneyCEOSell3,036$67.50$204,930.00175,859View SEC Filing  
5/15/2014Robert PerezCOOSell1,518$67.50$102,465.0045,869View SEC Filing  
5/15/2014Steven GilmanEVPSell16,340$67.82$1,108,178.8027,598View SEC Filing  
5/14/2014Michael BonneyCEOSell3,840$69.00$264,960.00172,645View SEC Filing  
5/14/2014Robert PerezCOOSell2,400$69.00$165,600.0044,262View SEC Filing  
5/14/2014Steven GilmanEVPSell1,680$69.00$115,920.0026,313View SEC Filing  
3/6/2014Gregory SteaSVPSell19,889$79.74$1,585,948.8616,276View SEC Filing  
2/27/2014Mark CorriganDirectorSell5,000$80.00$400,000.005,498View SEC Filing  
2/27/2014Michael BonneyCEOSell100,000$81.25$8,125,000.00168,485View SEC Filing  
2/27/2014Robert PerezCOOSell30,000$80.18$2,405,400.0041,662View SEC Filing  
2/20/2014Michael BonneyCEOSell3,112$75.60$235,267.20168,485View SEC Filing  
2/3/2014Kenneth BateDirectorSell6,250$72.15$450,937.507,914View SEC Filing  
1/15/2014Gregory SteaSVPSell5,312$74.90$397,868.8014,189View SEC Filing  
1/15/2014Robert PerezCOOSell10,000$74.95$749,500.0037,612View SEC Filing  
1/13/2014Robert PerezCOOSell10,000$72.95$729,500.0037,612View SEC Filing  
1/9/2014Kenneth BateDirectorSell10,000$70.00$700,000.007,914View SEC Filing  
1/2/2014Steven GilmanEVPSell25,000$67.82$1,695,500.0023,540View SEC Filing  
12/2/2013Kenneth BateDirectorSell12,500$67.63$845,375.007,914View SEC Filing  
9/9/2013Martin RosenbergDirectorSell15,472$65.00$1,005,680.00View SEC Filing  
8/16/2013Robert PerezCOOSell1,024$60.55$62,003.2037,536View SEC Filing  
7/31/2013Gregory SteaSVPSell33,750$61.29$2,068,537.50View SEC Filing  
7/26/2013Nancy J HutsonDirectorSell5,000$53.87$269,350.00View SEC Filing  
7/19/2013Gregory SteaSVPSell4,375$55.00$240,625.00View SEC Filing  
6/3/2013Kenneth BateDirectorSell2,500$54.95$137,375.00View SEC Filing  
6/3/2013Steven C GilmanEVPSell15,125$54.49$824,161.25View SEC Filing  
5/24/2013Mark CorriganDirectorSell14,000$54.60$764,400.00View SEC Filing  
5/22/2013J Matthew SingletonDirectorSell27,500$55.48$1,525,700.00View SEC Filing  
5/20/2013Charles Anthony LaranjeiraSVPSell14,000$51.43$720,020.00View SEC Filing  
5/20/2013Michael W BonneyCEOSell60,000$50.00$3,000,000.00View SEC Filing  
5/20/2013Robert J PerezCOOSell15,000$49.98$749,700.00View SEC Filing  
5/16/2013Michael W BonneyCEOSell2,400$47.88$114,912.00View SEC Filing  
5/16/2013Robert J PerezCOOSell1,500$47.88$71,820.00View SEC Filing  
5/16/2013Steven C GilmanEVPSell1,201$48.88$58,704.88View SEC Filing  
5/15/2013Kenneth BateDirectorSell2,500$48.41$121,025.00View SEC Filing  
5/15/2013Michael W BonneyCEOSell2,979$48.41$144,213.39View SEC Filing  
5/15/2013Robert J PerezCOOSell1,490$48.41$72,130.90View SEC Filing  
5/15/2013Steven C GilmanEVPSell1,017$48.41$49,232.97View SEC Filing  
5/14/2013Michael W BonneyCEOSell3,753$49.18$184,572.54View SEC Filing  
5/14/2013Robert J PerezCOOSell2,346$49.18$115,376.28View SEC Filing  
5/14/2013Steven C GilmanEVPSell1,135$49.18$55,819.30View SEC Filing  
(Data available from 1/1/2013 forward)


Cubist Pharmaceuticals (NASDAQ CBST) News Headlines

Homology Medicines Appoints Mary Thistle to Board of DirectorsHomology Medicines Appoints Mary Thistle to Board of Directors - March 15 at 5:20 PM
After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? - December 9 at 8:50 AM
Merck to buy Cubist Pharmaceuticals for $8.4 billionMerck to buy Cubist Pharmaceuticals for $8.4 billion - December 8 at 6:09 PM
US STOCKS-Wall St falls with energy shares; global data disappointsUS STOCKS-Wall St falls with energy shares; global data disappoints - December 8 at 1:46 PM
Merck, Cubist Agree to $9.5 Billion AcquisitionMerck, Cubist Agree to $9.5 Billion Acquisition - December 8 at 8:20 AM

SEC Filings

Cubist Pharmaceuticals (NASDAQ:CBST) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Cubist Pharmaceuticals (NASDAQ:CBST) Income Statement, Balance Sheet and Cash Flow Statement


Cubist Pharmaceuticals (NASDAQ CBST) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.